SPECIAL FEATURES

Finding the Right Dose for Cancer Therapeutics—Can We Do Better?
Eric H. Rubin and Keaven M. Anderson
See article p. 1289

Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer
Amina Zoubeidi, Kim Chi, and Martin Gleave

Targeting the RB-pathway in Cancer Therapy
Erik S. Knudsen and Jean Y.J. Wang

A New Therapy Paradigm for Prostate Cancer Founded on Clinical Observations
Eleni Efstratiou and Christopher J. Logothetis

Contents

COMPLETED MICRORNA PROFILING FOR HEAD AND NECK SQUAMOUS CELL CARCINOMAS
Angela B.Y. Hui, Michelle Lenarduzzi, Tiffany Kruchsel, Levi Waldron, Melania Pintilie, Wei Shi, Bayardo Perez-Ordonez, Igor Jurisica, Brian O’Sullivan, John Waldron, Pat Gullane, Bernard Cummings, and Fei-Fei Liu

X-Linked Ectodermal Dysplasia Receptor Is Downregulated in Breast Cancer via Promoter Methylation
Vasu Punji, Hittu Matta, and Preet M. Chaudhary

Dasatinib Inhibits the Growth of Molecularly Heterogeneous Myeloid Leukemias

AZD8931, an Equimopotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer

Blockade of the Extracellular Signal-Regulated Kinase Pathway Enhances the Therapeutic Efficacy of Microtubule-Destabilizing Agents in Human Tumor Xenograft Models
Kazushi Watanabe, Susumu Tanimura, Aya Uchiyama, Toshiaki Sakamoto, Takumi Kawabata, Kei-ichi Ozaki, and Michihiko Kohno

HUMAN CANCER BIOLOGY

High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma

Frequent Downregulation of miR-34 Family in Human Ovarian Cancers

CANCER THERAPY: PRECLINICAL
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1179</td>
<td><strong>Low-Molecular-Weight Cyclin E Can Bypass Letrozole-Induced G1 Arrest in Human Breast Cancer Cells and Tumors</strong></td>
<td>Said Akli, Tuyen Bui, Hannah Wingate, Anna Biernacka, Kelly K. Hunt, and Khandan Keyomarsi</td>
</tr>
<tr>
<td>1191</td>
<td><strong>Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells</strong></td>
<td>Zhaojing Zhong, Kyla Driscoll Carroll, Desiree Policarpio, Carla Osborn, Michael Gregory, Rajiv Bassi, Xia Xia Jimenez, Marie Prewett, Gregory Liebisch, Kris Persaud, Douglas Burtrum, Su Wang, David Surguladze, Stanley Ng, Heather Griffith, Paul Balderes, Jacqueline Doody, Jonathan D. Schwartz, Haqop Yousouffian, Eric K. Rowinsky, Dale L. Ludwig, Larry Witte, Zhenping Zhu, and Yan Wu</td>
</tr>
<tr>
<td>1206</td>
<td><strong>Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography</strong></td>
<td>Nathalie Lassau, Serge Koscienly, Laurence Albige, Linda Chami, Baya Benatsou, Mohamed Chebil, Alain Roche, and Bernard J. Escudier</td>
</tr>
<tr>
<td>1236</td>
<td><strong>A 3′-Untranslated Region Polymorphism in IGF1 Predicts Survival of Non–Small Cell Lung Cancer in a Chinese Population</strong></td>
<td>Mingfeng Zhang, Zhibin Hu, Jinlin Huang, Yongqian Shu, Juncheng Dai, Guangfu Jin, Rong Tang, Jing Dong, Yi-jia Chen, Lin Xu, Xin-Hua Huang, and Hongbing Shen</td>
</tr>
<tr>
<td>1245</td>
<td><strong>Low Levels of Phosphorylated Epidermal Growth Factor Receptor in Nonmalignant and Malignant Prostate Tissue Predict Favorable Outcome in Prostate Cancer Patients</strong></td>
<td>Peter Hammarsten, Amar Karali, Andreas Josefsson, Stina Häggsström Rudolfsson, Pernilla Wikström, Lars Egevad, Torvald Granfors, Pär Stattin, and Anders Bergh</td>
</tr>
<tr>
<td>1256</td>
<td><strong>A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies</strong></td>
<td>D. Ross Camidge, Roy S. Herbst, Michael S. Gordon, S. Gail Eckhardt, Razelle Kurzrock, Blythe Durbin, Josephine Ing, Tanyi Gorton, Jason Sager, Avi Ashkenazi, Gordon J. P. Bray, and David Mendelson</td>
</tr>
<tr>
<td>1264</td>
<td><strong>Tipifarnib Plus Tamoxifen in Tamoxifen-Resistant Metastatic Breast Cancer: A Negative Phase II and Screening of Potential Therapeutic Markers by Proteomic Analysis</strong></td>
<td>Florence Dalenc, Sophie F. Doisneau-Siou, Ben C. Allal, Sabrina Marsi, Valérie Leurs-Cances, Karima Chaou, Odile Schiltz, Bernard Monsarrat, Thomas Filleron, Nicole Renée, Emilie Malaisse, Elise Meunier, Gilles Favre, and Henri Roché</td>
</tr>
</tbody>
</table>

Leona Downey, Robert B. Livingston, Maria Koehler, Michael Arbushites, Lisa Williams, Angela Santiago, Roberta Guzman, Ivonne Villalobos, Angelo Di Leo, and Michael F. Press

Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse

Rajul K. Jain, J. Jack Lee, David Hong, Maurie Markman, Jing Gong, Aung Naing, Jennifer Wheler, and Razelle Kurzrock

See commentary p. 1085

Phase I Trial of Pelvic Radiation, Weekly Cisplatin, and 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, NSC #663249) for Locally Advanced Cervical Cancer

Charles A. Kunos, Steven Waggoner, Vivian von Gruenigen, Elisa Eldermire, John Pink, Afshin Dowlati, and Timothy J. Kinsella

Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy

Dae Ho Lee, Keunchil Park, Joo Hang Kim, Jong-Seok Lee, Sang Won Shin, Jin-Hyoung Kang, Myung-Ju Ahn, Jin Seok Ahn, Cheolwon Suh, and Sang-We Kim

Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041)


Potential Clinical Significance of a Plasma-Based KRAS Mutation Analysis in Patients with Advanced Non–Small Cell Lung Cancer

Shuhang Wang, Tongtong An, Jie Wang, Jun Zhao, Zhihui Wang, Mingle, Hua Bai, Lu Yang, Yan Zhang, Xin Wang, Jianchun Duan, Yuyan Yang, Qingzhi Guo, and Meina Wu

Smoking and Colorectal Cancer in Lynch Syndrome: Results from the Colon Cancer Family Registry and The University of Texas M.D. Anderson Cancer Center

Mala Pande, Patrick M. Lynch, John L. Hopper, Mark A. Jenkins, Steve Gallinger, Robert W. Haile, Loic LeMarchand, Noralane M. Lindor, Peter T. Campbell, Polly A. Newcomb, John D. Potter, John A. Baron, Marsha L. Frazier, and Christopher I. Amos

Studies of TMPRSS2-ERG Gene Fusions in Diagnostic Trans-Rectal Prostate Biopsies

Gerhardt Attard, Johann S. de Bono, Jeremy Clark, and Colin S. Cooper

In Response

Martin G. Sanda

Vascular Endothelial Growth Factor Concentration as a Predictive Marker: Ready for Primetime?

Peter A. Kavas, Hal Hinte, and Sebastien J. Hotte

In Response

Emer O. Hanrahan, Anderson J. Ryan, and John V. Heymach

Correction: A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors

Correction: The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y] Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin’s Lymphoma: Preclinical Findings and Results of a Phase I Trial

The Journal of Clinical and Translational Research
ABOUT THE COVER

Expression of the miR-34 family was found to be frequently reduced in human epithelial ovarian cancer, particularly so in tumors with p53 mutations. The figure shows miR-34a expression (dark blue) in ovarian serous adenocarcinoma as determined by in situ hybridization with locked nucleic acid–modified probes. Immunohistochemistry in serial sections revealed significant inverse correlation between miR-34a and its target MET, an oncogene commonly overexpressed in advanced stages of cancer. For details, see the article by Corney and colleagues on page 1119 of this issue.